For the quarter ending 2025-09-30, VOR had -$32,357K decrease in cash & cash equivalents over the period. -$53,906K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -812,684 | -1,606,155 |
| Depreciation expense | 2 | 2,862 |
| Acquisition of in-process research and development | - | 222,592 |
| Non-cash lease expense | 60 | 5,480 |
| Stock-based compensation | 8,029 | 3,777 |
| Transaction costs for issuance of pre-funded warrants | 643 | - |
| Change in fair value of warrant liabilities | 2,090,379 | - |
| Interest amortization on marketable securities | 11 | 22 |
| Loss on sale of property and equipment | 0 | -3,303 |
| Issuance of pre-funded warrants in connection with the acquisition of in-process research and development | 177,377 | - |
| Operating lease liabilities | -20 | -2,327 |
| Prepaid expenses and other current assets | 75 | -2,632 |
| Accounts payable, accrued liabilities and other current liabilities | 5,001 | -277 |
| Other assets | -151 | -1,963 |
| Net cash used in operating activities | -53,662 | -66,250 |
| Purchases of marketable securities | 0 | 0 |
| Proceeds from maturities of marketable securities | 0 | 0 |
| Purchases of property and equipment | 244 | 383 |
| Proceeds from sales of property and equipment | 0 | 799 |
| Net cash provided by investing activities | -244 | 416 |
| Payment of issuance costs related to private placement and pre-funded warrants | 643 | 551 |
| Proceeds from the issuance of pre-funded warrants | 0 | 175,000 |
| Proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs | 20,257 | 0 |
| Repurchases of shares for tax withholdings upon vesting of restricted stock unit awards | 19 | 87 |
| Proceeds from stock option exercises and the issuance of shares under espp | 1,954 | 97 |
| Net cash provided by financing activities | 21,549 | 174,459 |
| Net increase in cash, cash equivalents and restricted cash equivalents | -32,357 | 108,625 |
| Cash and cash equivalents at beginning of period | 84,362 | - |
| Cash and cash equivalents at end of period | 160,630 | - |
Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR)